Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.

3 Sep 2012

Study establishes association of IL-16 with prostate cancer in African-American men

Prostate cancer in African-American men is associated with specific changes in the IL-16 gene, according to researchers at the University of Illinois at Chicago College of Medicine.

1 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

1 Sep 2012

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

31 Aug 2012

Janssen submits bedaquiline MAA with EMA for treatment of multi-drug resistant tuberculosis

Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

31 Aug 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

MidCap, EpiCept amend Loan and Security Agreement

EpiCept Corporation announced today that it has amended the Company's Loan and Security Agreement with MidCap Financial, LLC effective August 27, 2012.

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed - but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

31 Aug 2012

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.

31 Aug 2012

Emergency readmission after endoscopy linked to mortality risk

The risk for mortality is significantly increased among patients who are readmitted urgently following endoscopy, compared with other endoscopy patients, a UK study shows.

30 Aug 2012

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

For patients with recurring head and neck cancer, stereotactic body radiotherapy offers a feasible and tolerable salvage treatment, with median overall survival rates of more than 1 year, report researchers.

30 Aug 2012

Closing in on neurologic biomarker diagnosis

A panel of five cerebrospinal fluid biomarkers may help doctors to accurately diagnose patients with various forms of dementia and parkinsonian disorders, research published in the Archives of Neurology suggests.

30 Aug 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

CCE, Accretive Health partner to develop novel oncology care management

Accretive Health, Inc., a healthcare technology and services company, and Cancer Clinics of Excellence (CCE), a national network of practice-owned, physician-driven community-based oncology practices, announced today that they have partnered to develop a novel, end-to-end oncology care management offering designed to enable healthcare providers to improve the efficacy and quality of cancer care while simultaneously improving the affordability of the healthcare system.

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

NCCN announces new guidelines for patients with pancreatic Cancer

The National Comprehensive Cancer Network (NCCN), with the support of the Pancreatic Cancer Action Network, announces the latest addition to the library of NCCN Guidelines for PatientsTM, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

30 Aug 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.

30 Aug 2012

Oncology News and Research

Further Reading

Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

Study establishes association of IL-16 with prostate cancer in African-American men

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

Janssen submits bedaquiline MAA with EMA for treatment of multi-drug resistant tuberculosis

Weill Cornell Medical College receives three new research grants for translational blood cancer study

MidCap, EpiCept amend Loan and Security Agreement

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Emergency readmission after endoscopy linked to mortality risk

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

Closing in on neurologic biomarker diagnosis

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

CCE, Accretive Health partner to develop novel oncology care management

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

NCCN announces new guidelines for patients with pancreatic Cancer

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News